James Gale is listed as a director on 14 SEC Form D filings by 2 issuers between Jun 2021 and Aug 2026: Pharmaceutics International, Inc. (Hunt Valley, MD — pharmaceuticals — 2021–2024; $108M reported sold to 9 investors) and Cerium Pharmaceuticals, Inc. (Gaithersburg, MD — pharmaceuticals — 2021–2026; $8.9M reported sold to 9 investors).
What this means 2 separate companies raised money with this person listed as director, over about 5 years. Across those companies the filings report $116.9M sold in total.
Listed alongside David Solomon (12 shared filings), Michael Bogda (12 shared filings), John Guthrie (8 shared filings), Syed E. Abidi, Ph.D. (8 shared filings), John Fowler (7 shared filings) and 14 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around James. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 14 public filings for James Gale and found 12 differences, 2 worth asking the sponsor about: Form D filed 76 days after the first sale; Form D filed 155 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.